⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IONS News
Ionis Pharmaceuticals, Inc. Common Stock
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
businesswire.com
IONS
New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia USA - English USA - English
prnewswire.com
IONS
New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia
prnewswire.com
IONS
Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight
globenewswire.com
IONS
ALNY
NVS
BIIB
ARWR
SLN
WVE
VNDA
NSP
TCRT
AMX
CDIO
SRPT
VIR
BNTX
ARCT
GSK
PFE
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
businesswire.com
IONS
BIIB
Longwood Healthcare Leaders to Host MIT CEO, Off-the-Record Networking and Discussion Forum, Convening Life Science Thought Leaders at MIT Koch Institute
accessnewswire.com
BIIB
ALNY
MRNA
REGN
JNJ
BEAM
IONS
Ionis to present at upcoming investor conferences
businesswire.com
IONS
Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight
globenewswire.com
AZN
IONS
ARWR
REGN
SNY
OMER
IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight
globenewswire.com
NVS
VRTX
BIIB
VTRS
AZN
IONS
TAK
ARWR
WLDN
Form 8-K
sec.gov
IONS